Calcium absorption response to cholecalciferol supplementation in hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 6, 2013, Pages 1003-1008

  Armas, Laura A G ^a   Zena, Mohsen ^a   Lund, Richard ^b   Heaney, Robert P ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM CARBONATE; COLECALCIFEROL;

ADULT; AGED; ARTICLE; CALCIUM ABSORPTION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; FEMALE; HEMODIALYSIS; HUMAN; IMMUNORADIOMETRIC ASSAY; KIDNEY FAILURE; MALE; RADIOIMMUNOASSAY; RENOVASCULAR HYPERTENSION; VITAMIN SUPPLEMENTATION;

AGED; CALCIUM CARBONATE; CALCIUM, DIETARY; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; NEBRASKA; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMINS;

EID: 84878821896     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08610812     Document Type: Article

References (36)

1. Liu PT, Stenger S, Li H,Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773, 2006
2. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
3. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003
4. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S: Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am J Kidney Dis 58: 374-382, 2011
5. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A: Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 5: 905-911, 2010
6. Blair D, Byham-Gray L, Lewis E, McCaffrey S: Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 18: 375-382, 2008
7. Kumar VA, Kujubu DA, Sim JJ, Rasgon SA, Yang PS: Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol 24: 98-105, 2011
8. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW: Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105: c132-c138, 2007
9. Vergne-Marini P, Parker TF, Pak CY, Hull AR, DeLucaHF, Fordtran JS: Jejunal and ileal absorption in patients with chronic renal disease. Effect of 1alpha-hydroxycholecalciferol. J Clin Invest 57: 861-866, 1976
10. Peacock M: Calcium metabolismin health and disease. Clin Jam Soc Nephrol 5[Suppl 1]: S23-S30, 2010.
11. Armas LAG, Andukuri R, Barger-Lux J, Heaney RP, Lund R: 25- Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 7: 1428-1434, 2012
12. Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T,Weiner SM, Rump LC: High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 23: 4016-4020, 2008
13. Jean G, Souberbielle JC, Chazot C: Monthly cholecalciferol administration in haemodialysis patients: A simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 24: 3799-3805, 2009
14. Heaney RP, Dowell MS, Hale CA, Bendich A: Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22: 142-146, 2003.
15. Heaney RP: The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 97: 13-19, 2005
16. Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Napoli JL: Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clin Chem 42: 586-592, 1996
17. Heaney RP: Quantifying human calcium absorption using pharmacokinetic methods. J Nutr 133: 1224-1226, 2003.
18. Correcting the calcium. BMJ 1: 598, 1977.
19. Heaney RP, Skillman TG: Secretion and excretion of calcium by the human gastrointestinal tract. J Lab ClinMed 64: 29-41, 1964.
20. Hou SH, Zhao J, Ellman CF, Hu J, Griffin Z, Spiegel DM, Bourdeau JE: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 18: 217-224, 1991
21. Andress DL: Bone and mineral guidelines for patients with chronic kidney disease: A call for revision. Clin J AmSoc Nephrol 3: 179-183, 2008
22. Brown E, Juppner H: Parathyroid hormone: Synthesis, secretion, and action. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th Ed., edited by Christakos S, The American Society for Bone and Mineral Research, 2006, pp 90-98.
23. Heaney RP, Dowell MS, Barger-Lux MJ: Absorption of calcium as the carbonate and citrate salts, with some observations on method. Osteoporos Int 9: 19-23, 1999
24. Meyer J, Fullmer CS, Wasserman RH, Komm BS, Haussler MR: Dietary restriction of calcium, phosphorus, and vitamin D elicits differential regulation of the mRNAs for avian intestinal calbindin- D28k and the 1,25-dihydroxyvitamin D3 receptor. J Bone Miner Res 7: 441-448, 1992
25. Reinhardt TA, Horst RL: Parathyroid hormone down-regulates 1,25-dihydroxyvitamin D receptors (VDR) and VDR messenger ribonucleic acid in vitro and blocks homologous up-regulation of VDR in vivo. Endocrinology 127: 942-948, 1990
26. Hoenderop JGJ, Nilius B, Bindels RJM: Calcium absorption across epithelia. Physiol Rev 85: 373-422, 2005
27. Lund RJ, Andress DL, Amdahl M, Williams LA, Heaney RP: Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol 31: 165-170, 2010
28. Coburn JW, Koppel MH, Brickman AS, Massry SG: Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 3: 264-272, 1973
29. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46: 855-861, 1994
30. Recker R, Schoenfeld P, Letteri J, Slatopolsky E, Goldsmith R, Brickman A. The efficacy of calcifediol in renal osteodystrophy. Arch Intern Med 138: 857-863, 1978
31. Malluche H, Werner E, Ritz E: Intestinal absorption of calcium and whole-body calcium retention in incipient and advanced renal failure. Miner Electrolyte Metab 1: 263-270, 1978
32. Raisz LG, Trummel CL, Holick MF, DeLuca HF: 1,25- dihydroxycholecalciferol: A potent stimulator of bone resorption in tissue culture. Science 175: 768-769, 1972
33. Holick MF, Garabedian M, DeLuca HF: 1,25- dihydroxycholecalciferol: Metabolite of vitamin D3 active on bone in anephric rats. Science 176: 1146-1147, 1972
34. Recker R, Schoenfeld P, Letteri J, Goldsmith R, Brickman AS: 25 hydroxyvitamin D (calcifediol) in renal osteodystrophy: Long term results of a six-center trial. Presented at the Fourth Workshop on Vitamin D, Berlin, West Germany, February 18-22, 1979
35. Fournier A, Bordier P, Gueris J, Sebert JL, Marie P, Ferriěre C, Bedrossian J, DeLuca HF: Comparison of 1 alphahydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: Greater effect of 25- hydroxycholecalciferol on bone mineralization. Kidney Int 15: 196-204, 1979
36. Heaney RP, Barger-Lux MJ, Dowell MS, Chen TC, Holick MF: Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab 82: 4111-4116, 1997